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ABSTRACT
Friedreich’s ataxia (FRDA) is a recessive autosomal ataxia caused by
reduced levels of frataxin (FXN), an essential mitochondrial protein that
is highly conserved from bacteria to primates. The exact role of frataxin
and its primary function remain unclear although this information would
be very valuable to design a therapeutic approach for FRDA. A main
difficulty encountered so far has been that of establishing a clear
temporal relationship between the different observations that could
allow a distinction between causes and secondary effects, and provide
a clear link between aging and disease development. To approach this
problem,wedevelopedacellularmodel inwhichwecan switchoff/on in
a time-controlled way the frataxin gene partially mimicking what
happens in the disease. We exploited the TALEN and CRISPR
methodologies to engineer a cell line where the presence of an
exogenous, inducible FXN gene rescues the cells from the knockout of
the two endogenous FXN genes. This system allows the possibility of
testing the progressionof diseaseand is avaluable tool for following the
phenotype with different newly acquired markers.
KEY WORDS: Cellular model, Disease development, Frataxin,
Genetic models, Zinc fingers
INTRODUCTION
Friedreich’s ataxia (FRDA) is an autosomal recessive
neurodegenerative disease with an occurrence of 1 in 50,000
individuals and onset usually before 25 years of age (Cossée et al.,
1997). The pathophysiology of the disease is associated with
progressive neurodegeneration, spinocerebellar ataxia, sensory
loss and hypertrophic cardiomyopathy (Pandolfo, 2009).
A homozygous GAA triplet expansion in the first intron of the
frataxin gene (FXN) is the cause of the disease in 96% of
individuals with FRDA. This expansion is probably responsible for
epigenetic modifications upstream of the expansion and
consequent silencing of the FXN gene (Saveliev et al., 2003;
Sandi et al., 2013). Normal individuals carry around 40 copies of
the GAA triplet but individuals with FRDA present larger
expansions, usually up to 600-900 GAA repeats (Campuzano
et al., 1996). The size of the expansion is directly correlated to the
speed of disease progression, indicating a connection between
frataxin expression levels and severity (Filla et al., 1996). A small
fraction (∼3%) of individuals with FRDA is heterozygous with one
allele carrying the triplet expansion and the other a loss-of-function
mutation. Interestingly, lack of FRDA patients with homozygous
nonsense mutations and embryonic lethality observed in Fxn-
knockout mice indicate the need for an at least partial expression of
the FXN gene at the early stages of embryonic development
(Cossée et al., 1999, 2000).
The tissues that are mostly affected by FRDA are sensory
neurons and cardiomyocytes, which are both tissues with high
content of mitochondria and high metabolism (Perdomini et al.,
2013). At the cellular level, the disease is characterized by
mitochondrial iron accumulation, increased oxidative stress and
abnormalities in iron-sulphur (Fe-S) cluster biogenesis (Pandolfo
and Pastore, 2009; Martelli and Puccio, 2014). Despite extensive
studies, it is still unclear which of these three cellular dysfunctions
are the main promoters of FRDA and which are secondary
phenotypes (Pandolfo and Pastore, 2009; Vaubel and Isaya, 2013;
Martelli and Puccio, 2014). Complete understanding of the disease is
also complicatedby the fact that the exact role andprimary functionof
FXN remains unclear, although the protein is known to have iron-
binding properties and to play an important role in the regulation of
Fe-S cluster biogenesis (Pastore and Puccio, 2013). FXN is an
essential protein highly conserved from bacteria to primates. It is
nuclearly encoded and produced in the cytoplasmas a 210 amino acid
protein that is then imported into the mitochondrion where it is
matured into its final form (residues 81-210) by the mitochondrial
processing peptidase (MPP) (Schmucker et al., 2008).
Many different approaches have been developed in the attempt to
identify the function of frataxin and its role in the onset of FRDA.
They were based either on biophysical and structural studies
(Pastore and Puccio, 2013) or on animal and cellular models
(Perdomini et al., 2013). In vivo iPSCs derived from FRDA patients
(Ku et al., 2010; Hick et al., 2013) and multiple conditional
knockout mice (Pook et al., 2001; Puccio et al., 2001; Simon et al.,
2004; Al-Mahdawi et al., 2008) were extensively used to investigate
the effects of frataxin depletion. However, due to the intrinsic
characteristics of these models, most studies could not explore the
time-course of the disease and the phenotype was tested at few
temporally spaced time points (Perdomini et al., 2013). Therefore,
the early events that lead to the disease onset have yet to be fully
understood. This knowledge would be crucial to allow us to
discriminate between the causes and the effects of the disease
(Pastore and Adinolfi, 2014).
Here, we describe a new cellular model in which expression of
frataxin can be regulated at will by engineering a cell line where
the presence of an exogenous, inducible FXN gene integrated in the
genome is used to compensate for the bi-allelic knockout of the
endogenous FXN gene. The knockout was carried out by gene
editing using a targeting construct with a selectable marker and
sequential rounds of selection. Two different custom gene-editingReceived 25 February 2015; Accepted 20 April 2015
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platforms were used to boost targeting frequencies and thus
facilitate the development of the cell line model to overcome the
low frequencies of knockout induced by traditional gene targeting
techniques: the transcription activator-like effector nucleases
(TALENs) (Cermak et al., 2011) and the clustered regularly
interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) (Mali
et al., 2013). They are the latest two members of the growing family
of genome editing systems (Gaj et al., 2013).
Although very different from one another, they share the same
basic molecular mechanism. Both are characterized by a DNA
recognition domain that faithfully binds the desired target sequence
and a cleaving domain that produces the double-strand break (DSB)
(Cermak et al., 2011). They create DSBs at specific genomic loci,
promoting homologous recombination, and efficiently increase
the frequencies of induced genome modifications (Gaj et al., 2013).
The DNA-binding domain of TALENs is directly derived from the
TAL effector proteins secreted by Xanthomonas bacteria, a class of
plant pathogens. It is made of highly conserved protein ‘modules’ of
33-34 amino acids with just two repeat variable di-residues (RVDs,
positions 12th and 13th) that allow for recognition of a single
nucleotide (Boch et al., 2009). The modularity of TAL effectors can
be implemented to generate DNA-binding domains of around 20
different units that confer a high degree of DNA-binding specificity.
TAL domains can be combined with an unspecific DNA-cleavage
domain (FokI) to produce DSBs at the desired genomic locus
(Cermak et al., 2011).
The CRISPR/Cas9 platform is directly based on a prokaryotic
immune system common tomany bacteria and archea that protects the
organism from exogenous genetic elements. In this case, the DNA
specificity is granted by RNA guides of around 20 nucleotides
homologous to the target DNA to be cleaved that guide the unspecific
nuclease Cas9 towards its target (Horvath and Barrangou, 2010).
Using these tools, we obtained what may be a powerful tool to
follow the progression of FRDA, which may finally allow us to
understand the molecular basis of this disease. The model will allow
us to quantify the effects of reduced levels of frataxin in a time-
controlled way.
RESULTS
Development of an inducible frataxin gene and stable
transfection
Complete silencing of the endogenousFxn gene induces interruption
of cell division and subsequent cell death in cell models (Calmels
et al., 2009), and is a lethal mutation that leads to premature death in
mouse embryos (Cossée et al., 2000). The first step towards the
development of our cell model was thus to introduce an inducible
exogenous FXN gene that would rescue cells that underwent
homozygous knockout of the endogenous FXN gene from premature
cell death. We decided to rely on the ‘Flp-in T-REx’ (HEK293)
system (Life Technologies) to achieve a tightly controlled expression
of exogenous FXN as it allows generation of stable mammalian cell
lines using Flp-recombinase-mediated integration of an expression
cassette at a specific genomic location. This system has the
advantage of creating isogenic stable cell lines in which
controlled, high levels of expression of the desired gene are obtained.
The exogenous FXN cassette to be used in the inducible system
was created using the cDNA of human full-length FXN (amino
acids 1-210, RefSeq FXNNM_000144, hereafter called cFXN).
The cDNA was cloned into the pcDNA5/FRT/TO plasmid and
was co-transfected with the Flp-recombinase expression vector
(pOG44) in Flp-in T-REx cells. The pcDNA5/FRT/TO plasmid
harbours a hygromycin cassette that is expressed only when the
plasmid is correctly integrated in the FRT locus carried by the Flp-in
T-REx cells. Cells that underwent successful integration were
selected for 15 days in 10 cm plates using hygromycin. Single
colonies were isolated and expanded. The cell line generated was
dubbed T-REx293-cFXN.
Characterization of the inducible FXN cell line
The cFXN cassette is under the control of the tetracycline-regulated
promoter CMV-TetO2 (Yao et al., 1998) that is bound and
repressed, in absence of tetracycline, by the tet-repressor protein
expressed by the stably integrated regulatory plasmid pcDNA6/TR.
A 3× FLAG tag (peptide sequence DYKDDDDK) was cloned
downstream of the gene (i.e. at the C terminus of the expressed
frataxin protein) to monitor the levels of expression of the cFXN
cassette over time (Fig. 1A). We confirmed expression of the cFXN
cassette under induction with increasing amounts of tetracycline by
detection of the FLAG tag in western blot assays using a specific
anti-FLAG antibody. The resulting expression of cFXN was
dependent on the concentration of tetracycline, indicating a good
level of control on the induction of the exogenous gene and
therefore giving us the ability to modulate the amount of expressed
protein. Levels of protein expression were assessed by comparing
them with those of the endogenous β-actin protein (Fig. 1B).
TRANSLATIONAL IMPACT
Clinical issue
Friedreich’s ataxia (FRDA) is a recessive autosomal form of ataxia that is
characterized by neurodegeneration, loss of muscle coordination and
hypertrophic cardiomyopathy. It is caused by reduced levels of frataxin
(FXN), an essential mitochondrial protein that is involved in the regulation
of iron-sulfur cluster biogenesis and that is highly conserved from
bacteria to primates. The exact role of FXN and its primary cellular
functions in sensory neurons and cardiomyocytes – the cell types that
are mostly affected in FRDA – remain largely unclear. However, this
information is crucial for designing therapeutic approaches for FRDA and
for understanding the molecular mechanisms of this disease. One main
difficulty is that current experimental models are not able to follow the
progression of the disease, which could allow researchers to distinguish
causative mechanisms from secondary effects, thus gaining more
insights into the molecular basis of FRDA.
Results
This work describes the development of a new cellular model of FRDA to
study the disease progression and phenotypes in a time-controlled
manner. The authors used a human cell line in which they first introduced
an exogenous inducible form of the gene and then knocked down the
endogenous FXN gene by using two gene-editing platforms: the
transcription activator-like effector nucleases (TALENs) and the
clustered regularly interspaced short palindromic repeats/Cas9
(CRISPR/Cas9). Immunofluorescence and western blot analyses
revealed that this approach successfully enables switching off and on
the FXN gene in the cells in a time-controlled way, partially mimicking
what happens in the disease.
Implications and future directions
This new cellular model of FRDA offers the possibility of studying the
effects of FXN depletion at different time points to better understand the
early stages and progression of the disease. It has also the potential to
use available markers, e.g. indicators of iron-sulphur cluster biogenesis,
to characterize and follow FRDA phenotypes over time. In addition, the
genome-editing techniques used here could be adapted for use in
induced pluripotent stem cells, which can be differentiated in either
neuronal or cardiac cells, allowing for the time-resolved characterization
of FRDA phenotypes in relevant cell types.
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Subsequently, we assessed the half-life of the induced FXN protein
in cells after removal of tetracycline from the culture medium.
T-REx293-cFXN cells were induced for 48 h with tetracycline. Cell
samples were then collected every 24 h (Fig. 1B). Already after 24 h
the unprocessed, cytosolic form of FXN (amino acids 1-210) was
barely detectable, while the mitochondrial form (amino acids
81-210) persisted for a period of 5 days before becoming
undetectable. Finally, we confirmed mitochondrial localization of
the matured exogenous FXN protein by immunofluorescence
(Fig. 1C).
Design of FXN-specific TALENs and CRISPRs
Identification of suitable target sequences to be used with the
TALEN platform was carried out by querying the web-based
software TALE-NT 2.0 (Doyle et al., 2012) with the human FXN
gene (Gene ID: 2395). The software identifies possible sites using
parameters based on a previously described protocol (Cermak et al.,
2011): the length of the target sequences for each TAL-binding
domain (half binding domains, either on the right or left of the
cutting site) was set to be between 15 and 20 bp. The spacer
sequence, the nucleotide region where the cutting will occur, was set
Fig. 2. FXN target sequences. Exons 3 and 4 of
FXN with surrounding areas drawn to scale. Exons
are shown as black boxes; introns are black lines.
The target sequences for both TALENs and
CRISPRs are graphically represented as small
white boxes and also as full nucleotide sequences.
Fig. 1. Testing controlled exogenous FXN expression. (A) The exogenous inducible cFXN cassette. The inducible promoter TetO2 is shown in red, the cDNA
frataxin gene in yellow and the 3× FLAG tag in green. (B) Western blot showing the correlation between tetracycline concentrations and levels of cFXN
expression (left). Stability of the exogenous frataxin protein after suspension of tetracycline induction (right). Antibodies against β-actin were used as controls.
(C) Immunofluorescence confirms themitochondrial localization of the induced frataxin protein. The nuclear DNAwas stained with DAPI (blue), mitochondria with
MitoTracker red (red) and cFXN-FLAG protein with monoclonal anti-FLAG (primary antibody) and AlexaFluor-488 (secondary antibody) (green).
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to a length of 10-16 bp. TALENs predicted by TALE-NT 2.0 using
these settings would identify target sequences of at least 40 bp, a
nucleotide length that guarantees high specificity and reduces the
risk of off-target cleavage events (Fig. 2).
Of all possible target sequences originated by TALENT 2.0, five
were chosen for their relative positions to FXN exons and, when
possible, for the presence of suitable unique restriction sites for the
following cutting efficiency assay (see below). The relative TAL-
binding domains were generated by the Golden Gate approach using
the TAL archive provided by Addgene. Four out of the five pairs of
TAL-binding domains (one left and one right for each pair) were
cloned in the expression vector pcGoldyTALEN (TALEN-I3.1,
-I3.2, -I3.3 and -I4) (Bedell et al., 2012; Carlson et al., 2012),
whereas TALEN-I2 was created using the pCS2TAL3-RRR and
-DDD expression vectors (Dahlem et al., 2012). These last two
expression vectors encode two mutated half nuclease domains that
transform the homodimer FokI into an obligate heterodimer. These
alternative expression plasmids were chosen after preliminary
results on the cutting efficiencies of the first four TALENs showed
unsatisfactory levels of target sequence cleavage.
An alternative engineered endonuclease platform, CRISPR/Cas9,
was used to increase the chances of effectively targeting the FXN
gene. Two different CRISPRs (CRISPR-I3 and -I4) were generated
using a kit provided by Addgene according to the Church lab’s
approach (Fig. 2) (Mali et al., 2013). The target sequences were
selected from a library of more than 190,000 sequences previously
created to facilitate the selection process because of their proximity
to the FXN exons (Mali et al., 2013).
Detection of TALEN- and CRISPR-induced FXN-specific
modifications
To assess cleavage of FXN by either TALENs or CRISPRs in human
cells, we transfected T-REx293-cFXN cells with either TALEN or
CRISPR expression vectors. Transfected cells were collected after
48 h and genomic regions surrounding TALEN and CRISPR target
sequences of FXNwere amplified by PCR. Two different approaches
were adopted to detect the formation of indels resulting from
inaccurate NHEJ at the target site. When possible, NHEJ-induced
loss of unique restriction sites at the target sequences was detected by
restriction digestion of the amplicons (TALEN-I2, -I3.1 and -I3.2)
followedbygel electrophoresis. The presence of indelswas confirmed
by identification of uncut product (Fig. 3A,B).
Alternatively,we used theSurveyor nuclease assay (Trangenomic) to
detect the formation of indels (TALEN-I3.3, -I4, CRISPR-I3 and -I4).
Surveyor nuclease, which cleaves short regions of heteroduplex
DNA, cleaved the PCR amplicons into two fragments of sizes
expected for heteroduplex formation at the target sites of the
endonucleases (Fig. 3C,D).
Fig. 3. TALEN andCRISPR cutting efficiencies. 2×105 T-REx293-cFXN cells were plated in six-well plates 48 h before transfection. Cells were transfected with
2.5 μg of DNA. Genomic DNA isolated from cells 48 h after transfection was used as a template to amplify DNA fragments surrounding the relative TALENs and
CRISPRs target sequences by PCR. (A) PCR products for the region surrounding TALEN-I2 target sequence were digested with the unique restriction enzyme
AseI. Lane 1, undigested PCR product used as a reference; lane 2, digested PCR product from negative control; lanes 3 and 4, digested PCR products from two
separate cells samples transfected with TALEN-I2 expression vectors. (B) PCR products for the region surrounding TALEN-I3.1 and TALEN-I3.2 target
sequences were digested with the unique restriction enzymes XmnI and BplI, respectively. Lane 1, undigested PCR product used as a reference; lane 2,
XmnI-digested PCR product from negative control; lane 3,XmnI-digested PCR product from cells transfected with TALEN-I3.1; lane 4,BplI-digested PCR product
from cells transfected with TALEN-I3.2. (C) PCR products from genomic DNA of TALEN-I3.3 and -I4 transfected cells were digested with Surveyor endonuclease.
Lanes 3 and 6, undigested PCR products; lanes 4 and 7, Surveyor-digested PCR products from negative controls; lanes 5 and 8, Surveyor-digested PCR
products from cells transfected with TALEN-I3.3 and -I4 vectors, respectively. Lanes 1 and 2 have been excised for clarity. (D) PCR products from genomic DNA of
CRISPR-I4- and -I3-transfected cells were digested with Surveyor endonuclease. Lanes 1 and 4, undigested PCR products; lanes 2 and 5, Surveyor-digested
PCR products from negative controls; lanes 3 and 6, Surveyor-digested PCR products from cells transfected with CRISPR-I4 and -I3 vectors, respectively. Red
arrows indicate the presence of TALEN-I2-, CRISPR-I3- and CRISPR-I4-induced indels in the relative amplicons.
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Cutting efficiencies varied greatly for each endonuclease tested.
TALEN-I3.1, -I3.2, -I3.3 and -I4 completely failed to show any sign
of cleavage activity (Fig. 3B,C). Digested PCR products originating
from genomic DNA of TALEN-I2-treated cells instead showed the
presence of a clear uncut band (Fig. 3A). The negative control, a
sample obtained by transfecting cells with pmaxGFP vector,
showed complete digestion of the amplicon, indicating that only
TALEN-I2 related amplicons carried indels. Interestingly, TALEN-
I2 was the only TALEN developed using the alternative expression
vectors pCS2TAL3-RRR/DDD, indicating a possible problem with
the pcGoldy-TALEN vector.
The Surveyor assay performed on amplicons derived from
CRISPR-treated cells indicated that both CRISPR-I3 and -I4
successfully cut their relative target sequences (Fig. 3D).
Surveyor-induced cleavage of amplicons was detected only in
samples derived from cells transfected with the CRISPR expression
vectors and not in the relative negative controls. Although it is not
possible to quantitatively compare the results obtained from the
TALEN-I2, CRISPR-I3 and -I4 due to the differences between
the performed assays (loss of restriction site and Surveyor),
CRISPR-I3 seemed to show the greatest cutting efficiency.
Homology directed knockout of the endogenous FXN gene
We next proceeded to produce gene targeting at the endogenous
FXN gene using the most suitable endonuclease of the successful
TALEN-I2, CRISPR-I3 and -I4. CRISPR-I4 was chosen because
of the position of its target sequence being relatively close to FXN
exon 4 and its cutting efficiency. To achieve successful knockout
of the target gene, we made a targeting construct (pFSVpur-LoxP-
TC-I4) designed to introduce a puromycin resistance (PuroR)
cassette at the CRISPR-I4 target site (Fig. 4A). The targeting
construct was designed to carry the PuroR cassette flanked by two
arms of homology specific for the targeted region of FXN.
Additionally, two LoxP sites were cloned immediately upstream
and downstream of the selectable marker. Expression of Cre
recombinase in transfected cells will allow removal of the PuroR
cassette. The pFSVpur-LoxP-TC-I4 construct was designed to
completely remove, in case of successful CRISPR-I4-mediated
targeting, the endogenous FXN exon 4 and replace it with the
PuroR cassette.
We co-transfected T-REx293-cFXN cells with 2.5 μg of DNA,
varying the ratio of CRISPR-I4/hCas9 vectors and targeting
construct (Table 1). Negative controls were performed by
transfecting cells with the targeting construct and the hCas9
vector only. After transfection, cells were plated on 10 cm plates
and selected in puromycin for 15 days. Single colonies (20 for each
experiment) were collected and expanded to test possible targeted
events by a specific PCR assay (Fig. 4B; Table 1). The PCR assay
was carried out using two primers: one target specific and one
construct specific. PCR products of the correct size (1.8 kb),
therefore, would be produced only in the case of successful
targeting and not for randomly integrated events. Positive controls
for the PCR screening were obtained by mixing, in the PCR
reaction, the pFSVpur-TC-I4-PC plasmid with genomic DNA
originated from untransfected cells. Ten and nine clones out of 20
for experiments 1 and 2, respectively, gave positive results in the
PCR assay, while none of the negative controls produced PCR
products of the expected size. Although the number of screened
clones was not statistically significant, the targeting efficiency,
overall, was ∼50%. Moreover, the targeting frequencies seemed not
to be affected by the ratio of transfected CRISPR-I4/pFSVpur-
LoxP-TC-I4 vectors used in the two different experiments
(Table 1).
Fig. 4. CRISPR-I4 promotes targeted disruption of the FXN
gene. (A) Exon 4 of FXN is depicted (top) with flanking regions in
black (homologous to pFSVpur-LoxP-TC-I4) or grey. The vertical
red arrow shows the CRISPR-I4 target site. The targeting construct
(pFSVpur-LoxP-TC-I4) is shown below the FXN gene with dotted
lines indicating regions of homology with the target locus. LoxP
sites flanking the puromycin resistance are represented as two
black triangles. The result of CRISPR-I4-promoted homologous
recombination between pFSVpur-LoxP-TC-I4 and the target locus
is shown at the bottom. Black and red horizontal arrows indicate
target-specific and construct-specific PCR primers, respectively.
Underneath are the expected PCR product and its expected size
(1.8 kb). (B) Agarose gel of the PCR screening assay for detection
of targeted events. C1, C3 and C4 products show the expected
1.8 kb band amplified from CRISPR-I4-, Cas9- and pFSVpur-LoxP-
TC-I4-transfected cells, respectively. The 1.8 kb PCR product
indicative of a successful targeting is indicated by the red arrow.
C2 shows an example of untargeted event. PC shows the PCR
product obtained using as a template the positive control plasmid
(pFSVpur-TC-I4-PC). NC1 and NC2 (negative controls) show the
absence of the characteristic 1.8 kb PCR band. These last two
samples were obtained from cells transfected with only Cas9 and
pFSVpur-LoxP-TC-I4 vectors.
Table 1. Targeting the endogenous FXN gene, as indicated by the
relative amount of the three different vectors (CRISPR-I4, hCas9 and






Experiment 1 0.5 μg 0.5 μg 1.5 μg 10/20
Experiment 2 1 μg 1 μg 0.5 μg 9/20
Negative
control
– 1 μg 1.5 μg 0/20
*Results are relative amount of transfected vector per sample.
‡Number of positive clones in the PCR screening assay compared with the
number of puromycin-resistant clones screened.
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Since its beginning more than 30 years ago (Thomas et al., 1986;
Thomas and Capecchi, 1987), genetic engineering has become an
invaluable tool in many different scientific and industrial fields.
Developments in genetic manipulation techniques have also pushed
the boundaries of what is possible by gene engineering. These
include a vast number of applications from the study of gene
function and the development of genetically modified organisms, to
gene therapy approaches such as gene addition and gene correction
(Yanez and Porter, 1998; Hacein-Bey-Abina et al., 2010; Nemudryi
et al., 2014). Probably the latest and more revolutionary
advancement in this field was the creation of a new family of
molecular tools that allows precise editing of virtually any desired
genomic sequence (Gaj et al., 2013; Nemudryi et al., 2014), starting
from the seminal 2006 paper on zinc finger nucleases (ZFNs)
(Wright et al., 2006) to the most recent introduction of CRISPRs
(Mali et al., 2013). These ‘molecular scissors’ have allowed a
cheaper, faster and more accurate alternative to traditional gene
targeting based on simple homologous recombination. The use of
TALEN/CRISPR nucleases is also a valuable alternative to RNAi
(RNA interference), especially for kinetic studies where the
phenotype has to be followed over a long time and where
uncontrolled levels of residual protein expression could affect the
outcome of the performed analysis. Although a valuable approach
for the study of gene function by knockdown, traditional RNAi is in
fact unsuitable in long-term studies because of its inability to
produce tightly controlled, long-term inhibition of the target gene
and by providing only incomplete repression of protein expression
(Gaj et al., 2013).
In this study, we aimed to develop and characterize FXN-specific
endonucleases for the generation of stable knockout cell lines to be
used in functional studies. We were prompted by the necessity of
distinguishing between causative processes and secondary effects in
the development of FRDA (Pastore and Adinolfi, 2014). This
necessity is particularly crucial with this disease because, almost
20 years after identification of the FXN gene, we still ignore the
disease mechanism or, more dramatically, what actually kills people
other than the reduced expression of FXN. Independent cellular and
animal models all revealed that FXN deficiency primarily leads to
defects in iron-sulphur cluster-containing proteins, but gave
contradictory results on whether accumulation of iron deposits is
a primary or secondary effect, and on the role of oxygen free-
radicals (ROS). In yeast, a defect in respiratory efficiency was
detected that follows disruption of iron-sulphur cluster maturation
(Muhlenhoff et al., 2002), whereas iron-sulphur cluster deficit was
described to precede the first evidence of a cardiac dysfunction in
mouse (Martelli et al., 2012). Interestingly, no evidence of oxidative
damage was observed in mouse and Drosophila models (Anderson
et al., 2005; Llorens et al., 2007), which fails to clarify whether ROS
is essential or even important to trigger the FRDA phenotype. This
conflicting evidence demanded the possibility of capturing the early
stages of disease and following disease development in a time-
resolved way starting from a precise time point. Previous attempts to
achieve this goal involved the use of conditional knockouts
developed by several different groups (Puccio et al., 2001;
Muhlenhoff et al., 2002; Martelli et al., 2012) and an RNAi-
mediated suppression strategy inDrosophila (Anderson et al., 2005;
Llorens et al., 2007). Our system, however, presents undoubtable
advantages over these models because of the complete efficiency of
gene silencing and its flexibility.
We used a parallel approach to increase the chance of obtaining an
effective knockout of the target gene and compare the efficiency of
TALEN and CRISPR platforms. In our hands, although both
CRIPSR-I4 and TALEN-I4 targeted the same region, downstream
of the exon 4, they showed distinctively different cleavage efficiency.
This cannot be ascribed to intrinsic characteristics of the different
targeted loci (accessibility and epigenetic modifications), indicating a
distinctive higher efficiency of CRIPSR-I4 at inducing DSBs.
Differences were also identified in the use of different TALEN
expression vectors. While TALENs developed using the pcGoldy-
TALEN vector (TALEN-I3.1, -I3.2, -I3.3 and -I4) performed poorly,
TALEN-I2, produced using the pCS2TAL3-RRR/DDD vector,
showed appreciable cutting activity. Both types of expression vector
harbour a modified TALEN backbone with truncated N- and
C-termini flanking the RVD cloning site, which has enhanced
binding activity (Miller et al., 2011;Mussolino et al., 2011) compared
to the traditional backboneusedbyCermaket al. (2011).Additionally,
pCS2TAL3-RRR/DDD vectors carry a modified nuclease domain
that renders the homodimeric FokI an obligate heterodimer. This
modification confers higher cleavage activity and, at the same time,
reduces the riskof off-target cleavage that is known to increase the risk
of undesired mutations and cell death (Doyon et al., 2011).
Of the three newly developed endonucleases that successfully
induced significant FXN-targeted modifications (TALEN-I2,
CRISPR-I3 and CRISPR-I4), we chose CRISPR-I4 for the
proximity of its target sequence to FXN exon 4. This allowed us
to create a targeting construct (pFSVpur-LoxP-TC-I4) that, when
integrated by homologous recombination, excised the exon
completely, replacing it with a puromycin resistance cassette.
Although integration of the selectable marker per se was enough to
disrupt the FXN gene, the need to produce knockout of both FXN
alleles still required two rounds of transfection with CRISPR-I4 and
the targeting construct because simultaneous homozygous FXN
knockout is a rare event. The presence of the puromycin cassette
flanked by two Lox-P sites allowed us to select the targeted cells in
the first round followed by Cre recombinase-mediated excision of
the puromycin cassette and a second round of targeting using the
same pFSVpur-LoxP-TC-I4 construct. The targeting experiments
carried out with CRISPR-I4 and pFSVpur-LoxP-TC-I4 showed a
targeting frequency of ∼50% to be compared to a 0% frequency
when cells were transfected with only pFSVpur-LoxP-TC-I4
targeting construct. This study, therefore, proves the feasibility of
successfully performing gene editing at the FXN locus.
The HEK293 cell line used in this project has some limitations as
an accurate representation of neuronal and cardiac cells, the two
main tissues affected in individuals with FRDA. It was nonetheless
selected because of its ease to work with, which allowed us to fully
assess the gene engineering techniques and initially test our
perspectives to assess disease progression. The techniques
developed here are incredibly flexible and will be used in the near
future to generate novel models based on cell types more relevant to
the study of FRDA. Our objective is to adapt the system to either
stem cells or induced pluripotent stem cells (iPSCs) in order to
develop a cell model that can be later on differentiated in either
neuronal or cardiac cells, allowing for the time-resolved
characterization of FRDA in relevant tissues and their comparison.
We are thus now in a strong position to follow and understand the
early stages in the development of FRDA. We also plan to monitor
the effects of FXN depletion using different biomarkers chosen
amongst the classical and newly developed ones. Along with the
established aconitase assay (an indicator of iron-sulphur cluster
biogenesis), we can, for example, test the new family of markers
developed for ROS detection, which were already shown to be
successful in FRDA studies (Albrecht et al., 2014). We are thus
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confident that our work will provide an important contribution to the
study and the diagnosis of FRDA.
MATERIALS AND METHODS
DNA constructs development
The pcDNA5-cFXN-FLAG expression vector was created by amplifying
the full-length FXN cDNA gene carried by the pTLXI plasmid [kindly
donated by Dr Mark Pook (Brunel University, London), FXN RefSeq
FXNNM_000144) using Q5 Hot Start High-Fidelity DNA polymerase
(NEB) with primers 5′-ATATTGGATCCGCCACCATGTGGACTCT-
CGGGCGC-3′ and 5′-ATATTCTCGAGGGCGGCAGCATCTTTTCC-
GGAATAGGCC-3′, digested with BamHI and XhoI (NEB) and cloned
in a modified pcDNA5™/FRT/TO inducible expression vector that carries
at the C terminus of the gene of interest a 3× FLAG tag.
To make the pFSVpur-LoxP-TC-I4 targeting construct, Q5 Hot Start
High-Fidelity DNA polymerase (NEB) was used to PCR amplify the
two homology arms from genomic DNA extracted from Flp-InT-REx-293
cells. The left homology arm (1.6 kb) was amplified with primers
5′-ATATTGAGCTCCATGATCCTGCCACTGCTGC-3′ and 5′-ATATT-
GCGGCCGCGGAGTTTGTGTAGGAAGAGCTTTGC-3′, digested with
SacI and NotI restriction enzymes (NEB) and cloned into pFSVpur-LoxP
vector (kindly donated by Dr Andrew Porter’s lab, Imperial College
London) to make pFSVpur-LoxP-TC-I4-left. The right homology arm
(1.6 kb) was amplified with primers 5′-ATATTCTCGAGCTGACACCT-
GTAATCCCAACAC-3′ and 5′-ATATTGGTACCGGGCAGTGTGT-
CCAAATACGATATG-3′, digested with XhoI and KpnI (Neb), and
cloned into pFSVpur-LoxP-TC-I4-left to create the final targeting
construct pFSVpur-LoxP-TC-I4. The pFSVpur-TC-I4-PC construct to
be used as a positive control during the PCR screening assay was
created by PCR amplification with Q5 Hot Start High-Fidelity DNA
polymerase (NEB) using primers 5′-CTCTCTGGAGGGCTAGCT-
GTAAAACGACGGCCAGT-3′ and 5′-CTGGGACTACACTGGCGTTA-
CCCAACTTAATC-3′ followed by digestion with DpnI (NEB) and blunt
ligation with T4 Ligase (NEB).
Cell culture and transfection
Flp-InT-REx-293 cells (Life Technologies) were cultured in DMEM
supplemented with 10% foetal bovine serum (FBS, Gibco), 10 mM
sodium pyruvate (Gibco), 20 mM L-glutamine (Life Technologies),
400 IU/ml penicillin-streptomycin (Life Technologies), 10 ml of a 100×
MEM-NEAA solution (Gibco), 15 μg/ml blasticidin (Life Technologies)
and 100 μg/ml zeocin (Life Technologies).
Stable and transient transfections of cells were carried out using
Lipofectamine 2000 (Life Technologies) following the manufacturer’s
instruction. Briefly, 2×105 cells were plated in a 6-well plate and transfected
48 h afterwards with 2.5 μg of total DNA. Transfection efficiencies were
estimated by transfecting 2.5 μg of a GFP expression vector (pmaxGFP,
Lonza) and flow cytometric analysis 48 h after transfection. Efficiency ranged
between 60% and 80%.
Generation of the stable T-REx293-cFXN cell line
Flp-InT-REx-293 cells were transfected using Lipofectamine, as previously
described, with 2.2 μg of pOG44 vector (expressing the Flp recombinase,
Life Technologies) and 0.3 μg of pcDNA5-cFXN-FLAG expression vector.
The vector harbour a FRT site that is used to stably integrate it by Flp-
mediated recombination with a specific FRT site already present in the
genome of the Flp-InT-REx-293 cells. Selection of suitable clones was
carried out for 12 days in 10 cm plates containing DMEM supplemented
with 100 μg/ml hygromycin (Life Technologies) and 15 μg/ml blasticidin
(Life Technologies).
Western blots
Assessment of cFXN expression in isolated T-REx293-cFXN clones
was carried out by plating of 1.5×105 cells in 12-well plate in presence of
100 μg/ml hygromycin and 15 μg/ml blasticidin, and increasing amounts
(1 to 100 ng/ml) of tetracycline (Sigma-Aldrich). Cells were collected after
48 h, pelleted by centrifugation and resuspended in 75 µl of RISC buffer:
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 2 mM MgCl2,
1 mMDTT, 1 mMPMSF (all reagents were purchased from Sigma-Aldrich)
and EDTA-free protease inhibitor (Roche). Cells were lysed for 1 h at 4°C
with shaking. Samples were centrifuged for 10 min at full speed to remove
pellet and protein concentration in the supernatant was measured using
Bio-Rad protein assay (OD595 nm). Total protein (25 and 50 μg) was
subjected to SDS-PAGE using precast 12% polyacrylamide gels (Life
Technologies). Samples were then transferred on nitrocellulose membrane
(0.2 μm pore size, Life Technologies) for 1 h using a semi-dry transfer
machine (Amersham). After 1 h blocking with PBS, 0.1% Tween-20
(Promega) and 5%milk membranes were incubated at 4°C with monoclonal
mouse ANTI-FLAG M2 antibody (1:10,000 dilution, Sigma-Aldrich).
After washes with PBS-0.1% Tween, membranes were incubated at room
temperature for 1 h with the secondary antibody goat anti-mouse IgG HRP
conjugate (1:4000 dilution, Millipore). Detection of samples was achieved
by incubating membranes with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific).
Immunofluorescence
T-REx293-cFXN cells grown on glass coverslips were treated with 100 nM
MitoTracker Red (Life Technologies) for 30 min, fixed with 4%
paraformaldehyde in DMEM at 37°C for 15 min and permeabilized for
5 min at room temperature with 0.3% Triton X-100 in PBS containing 5%
FBS. Samples were then washed and blocked with 5% FBS in PBS and
incubatedwithmonoclonal anti-FLAGM2 (Sigma-Aldrich) (1:2000 dilution)
at 4°C overnight. The following day, slides were washed and incubated with
the secondary antibody AlexaFluor-488 goat anti-mouse antibody (Life
Technologies) (1:1000 dilution) for 60 min at room temperature. After three
washes, slides were mounted with ProLong Gold Antifade Reagent that
includes 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain and imaged
using Delta vision Inverted microscope (Olympus).
Development of TALENs and CRISPRs
TALEN-binding domains were designed and developed following published
guidelines (Cermak et al., 2011). Each binding domain was created by two
rounds of the ‘Golden Gate’ assembly method (Cermak et al., 2011), where
each TAL module was linked together and cloned on a single plasmid
backbone using type IIS restriction enzymes BsaI and Esp3I. Full-length
constructs were subsequently cloned on either pcGoldy-TALEN (TALEN-
I3.1, -I3.2, I3.3 and I4) or on pCS2TAL3-RRR/DDD (TALEN-I2) expression
vectors for expression in human cells. The Golden Gate TALEN kit and
expression vectors were obtained from Addgene (Cambridge, MA, USA).
CRISPRs were designed following the Church’s protocol (Mali et al.,
2013). The expression vectors for the gRNAs were generated by ordering a
455 bp DNA fragment (composed of U6 promoter, target sequence, guide
RNA scaffold and termination signal) as gBlocks from IDT (Leuven,
Belgium) and then cloning them in pUC19 plasmid. The hCas9 expression
vector was instead obtained from Addgene.
Restriction digestion and surveyor (Cel-I) assays
TALEN-I2, -I3.1 and -I3.2 target sites harbour a unique restriction site that
can be used to identify TALEN-induced insertions/deletions (indels).
Briefly: 2×105 T-REx293-cFXN cells were plated in 6-well plate and
transfected 48 h after using Lipofectamine 2000 with 2.5 μg of vectors
encoding the relative TALENs. Genomic DNA was extracted 48 h after
transfection using the Wizard genomic DNA purification kit (Promega). Q5
Table 2. Primers and unique restriction sites used in the PCR/restriction






























Hot Start High-Fidelity DNA Polymerase (NEB) was used to amplify the
relative TALEN target regions (Table 2).
PCR products were purified using ZymoClean kit (ZymoResearch) and
digested with the respective unique restriction enzyme (Table 2). Digestion
products were then analysed either on 2% agarose or precast 10% TBE
polyacrylamide (Life Technologies) gels, depending on the size of the
original PCR product. The presence of TALEN-induced indels was
confirmed by identification of uncut products.
TALEN-I3.3-, -I4- and CRISPRs-induced indels were analysed using
the Surveyor kit assay (Transgenomic). Briefly, 2×105 T-REx293-cFXN
cells were plated in 6-well plates and transfected for 48 h using
Lipofectamine 2000 with 2.5 μg of vectors encoding the relative
TALENs or with 2.5 μg of vectors encoding Cas9 nuclease and relative
gRNA guides. Genomic DNA was extracted 48 h after transfection using
Quick-gDNA Microprep (ZymoResearch). Optimase high fidelity
polymerase (Transgenomic) was used to amplify the relative TALEN
target regions (Table 3). The generated PCR products were directly treated
with the commercially available Surveyor kit (Transgenomic) in
accordance with the manufacturer’s instructions. Results were visualized
on a precast 10% TBE polyacrylamide gel (Life Technologies).
Gene targeting
T-REx293-cFXN cells were transfected, following the protocol described
above, with 0.5 μg of pFSVpur-LoxP-TC-I4 targeting construct, 1 μg of
CRISPR-I4 vector and 1 μg of hCas9 vector orwith 1.5 μg of pFSVpur-LoxP-
TC-I4, 0.5 μg of CRISPR-I4 and 0.5 μg of hCas9. As a negative control, cells
were transfected with 1.5 μg of pFSVpur-LoxP-TC-I4 and 1 μg of hCas9.
Transfected cellswere expanded for 48 h. Selectionwith 0.4 μg/ml puromycin
was started and carried on for 15 days. Twenty puromycin resistant colonies
for each transfection were isolated and expanded. Genomic DNA for PCR
screening was isolated for each one of the selected colonies using Quick-
gDNAMicroprep (ZymoResearch). The target and construct specific primers
used for PCR screening were 5′-TGTAGTCCCAGCTCTCTGGAGG-3′ and
5′-GCATTCTAGTTGTGGTTTGTCC-3′, respectively. PCR screening was
carried out using KAPA HiFi hotstart DNA polymerase (Kapa Biosystems).
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